Damora Therapeutics, Inc. (formerly Galecto, Inc.) reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company, which focuses on developing therapies for hematologic disorders, particularly myeloproliferative neoplasms (MPNs), recorded a net loss of $209.8 million, a substantial increase from a loss of $21.4 million in the previous year. This increase is primarily attributed to a $174.3 million expense related to the acquisition of Damora Therapeutics, which was completed in November 2025, and a $9.4 million charge associated with the Paramora Warrant. Research and development expenses surged to $26.9 million, up from $6.4 million in 2024, reflecting heightened activity in preclinical studies and clinical trial preparations.
The acquisition of Damora Therapeutics was a pivotal strategic move for the company, enhancing its pipeline with three product candidates targeting mutant forms of the calcium-binding protein calreticulin (mutCALR). The lead candidate, DMR-001, is designed for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF), conditions that affect a significant number of patients in the U.S. The company plans to submit Investigational New Drug (IND) applications for DMR-001 and DMR-002 in mid-2026 and the second half of 2026, respectively, with the aim of initiating clinical trials thereafter.
Operationally, Damora Therapeutics is in the preclinical stage, with no products yet approved for commercial sale. The company reported having $257.6 million in cash and cash equivalents as of December 31, 2025, which it believes will fund operations into the Phase 3 development of DMR-001. However, the company anticipates needing substantial additional capital to support ongoing research and development activities, as well as to establish a commercial infrastructure for potential product launches. The company has indicated that it may seek to raise funds through various means, including public or private equity offerings.
The filing also highlighted several risks associated with the company's operations, including reliance on third-party collaborations, the unpredictability of clinical trial outcomes, and the potential for regulatory hurdles. Damora Therapeutics emphasized the importance of maintaining strong relationships with its collaborators, particularly Paragon Therapeutics, from which it has licensed rights to its product candidates. The company is also aware of the competitive landscape, noting that it faces significant competition from other biopharmaceutical companies developing therapies for similar indications.
Looking ahead, Damora Therapeutics remains focused on advancing its product candidates through clinical development while navigating the complexities of regulatory approval processes. The company’s ability to achieve its strategic objectives will depend on successful execution of its clinical trials, effective management of its financial resources, and the ability to adapt to the evolving biopharmaceutical landscape.
About Galecto, Inc.
Galecto, Inc. is a clinical-stage biotech developing small molecule therapeutics targeting fibrosis, cancer, and liver diseases. Its core products include GB3226, an AML inhibitor, and GB1211, a galectin-3 inhibitor for oncology and liver conditions. The company focuses on high unmet medical needs, leveraging its expertise in galectin biology to improve treatment options and enhance immunotherapy efficacy.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.